It has been suggested that in multifocal prostate cancer (PCa), focal therapy to the largest (index) lesion is sufficient, because secondary non-index lesions are unlikely to contribute to disease progression. In this study, the role of PCa focality in selecting men for focal therapy was evaluated. A histopathological analysis of the index and non-index lesions of 100 consecutive radical prostatectomy specimens was carried out. Cases that would have been suitable for focal ablation were also evaluated. Tumours were more often multifocal (78%) and bilateral (86%). In total, 270 tumour foci were identified. In multifocal disease, tumour volume, Gleason score and pathological stage were almost invariably defined by the index lesion of the specimen; among the 170 satellite foci, 148 (87%) were o0.5 cm 3 and 169 (99.4%) had Gleason score p6. Using the defined criteria, 51% of men in this series would have been considered suitable for focal ablation of the index lesion. Histological features of poor prognosis in the prostate are associated with the index lesion. There is a high proportion of patients who may be suitable for focal therapy, and clinical trials of index lesion ablation should be considered as part of this therapeutic strategy.
Introduction
Focal therapy has recently gained interest as a new method to control clinically localized prostate cancer (PCa) 1, 2 and has been defined as 'individualized treatment that selectively ablates known disease and preserves existing function, with the overall objective of minimizing morbidity without compromising life expectancy'. 3 The principal theoretical objection to focal prostate therapy includes the multifocal nature of PCa. However, recent histological studies within the PSAscreening era from the United States have shown that in men undergoing radical prostatectomy, 10-40% have unilateral disease [4] [5] [6] [7] [8] and 10-44% have unifocal tumours. [9] [10] [11] [12] These data raise the possibility that halfgland treatment (hemiablation) or focal ablation of tumour foci alone might be possible for between 10% and up to 50% of patients who would currently receive whole-gland treatment; on average, about one-third of men would be suitable. Furthermore, it has been suggested that in multifocal disease, the largest cancer focus (index lesion) determines disease progression and secondary lesions do not contribute to clinical outcome. [13] [14] [15] Therefore, targeting the index lesion alone may be sufficient. 1, 16, 17 Our objective was to examine the pathological features of clinically localized PCa in a UK series to (1) evaluate cancer focality and (2) determine the relationship between the index lesion and histological features of prognosis. These data may be useful for informing the design of clinical protocols assessing hemiablation, focal ablation or focal index lesion ablation.
Materials and methods

Patient population
A total of 100 consecutive cases of whole-mount radical prostatectomy specimens were selected for analysis from a single centre between the dates 1 July 2001 and 30 October 2003. Exclusion criteria included radiation therapy, transurethral resection or hormonal treatment before surgery.
Histopathological evaluation
Each prostatectomy specimen was totally embedded and processed by the whole-mount method. That is, after surgical resection, each prostate was fixed in 10% buffered neutral formalin for 24-48 h. After fixation, the apex and the base were amputated and serially sectioned parallel to the urethra. Seminal vesicles were sectioned parallel to the junction with the prostate. The remainder of the prostate gland was serially sectioned perpendicular to the longitudinal plane of the gland at 5-mm intervals and refixed for a further 24 h. From each 5-mm tissue block, a single 5-mm-thick section was generated and stained with haematoxylin-eosin.
In each prostate, areas of adenocarcinoma were identified and outlined with an ink tracing placed on each slide. Tumour grade for each prostate was determined according to the Gleason system. Pathological staging was based on the 1997 Tumour Node Metastasis system. For each tumour focus, volume was calculated using the cubic volume method that is, the raw product of tumour length, width and height of each focus (L ÂW Â H). 18, 19 Length was the longest linear dimension of the largest cross-sectional profile for that focus, and width was the second longest linear dimension in the maximum cross-sectional profile, approximately at right angles to the length. Height was defined as the number of cross-sections occupied by each focus multiplied by 0.5 cm, which was the thickness of each tissue block.
Three-dimensional reconstruction was performed by manually placing all slices in serial order and using the urethra as a reference point. When tumour areas were separated by 44 mm within the same slide [20] [21] [22] or 5 mm in adjacent slides, the areas were regarded as separate foci. When multifocal disease was observed, the index lesion was considered the largest focus as measured by volume, without considering its Gleason score. 15 Secondary foci were defined as all other smaller lesions. Laterality was determined using the urethra as the dividing line in the sagittal plane. Tumours were classified as unilateral if all the foci were completely confined to either the right or the left side of the prostate.
Suitability for focal therapy
Patients suitable for focal ablation (ablation of tumour focus alone with a small margin of normal tissue) were defined as follows:
(1) Unifocal cases: organ confined, Gleason score p7. Patients suitable for hemiablation (ablation of the entire one-half of the prostate) were defined as follows:
(1) Unilateral cases (unifocal or multifocal): organ confined with Gleason score p7. (2) Bilateral cases: organ confined, Gleason score p7, with the index lesion confined to one side of the gland and the contralateral side harbouring clinically insignificant secondary foci. 1 Patients with multifocal bilateral disease in which the index lesion occupied both sides of the gland were not considered suitable for focal therapy.
Database and statistical analysis
The following features were recorded for each case:
(1) age, (2) PSA, (3) pathological stage of the specimen, (4) focality and number of tumour foci, (5) tumour laterality, (6) volume of each tumour focus, total tumour volume (TTV) in the specimen and the total volume of the satellite foci of each specimen, (7) Gleason score of the specimen and Gleason score of each tumour focus, (8) extracapsular extension of each focus and (9) 
Results
Characteristics of PCas
The median age of the patients was 62 years (range: 48-74). PSA data were available for 81 patients (mean: 9.48 ng ml
À1
; range: 1.14-28 ng ml À1 ). Baseline characteristics of the 100 radical prostatectomies are presented in Table 1 and individual tumour characteristics in Table 2 . The mean TTV was 3.5 cm 3 (range: 0.03-24). The majority of the cases were multifocal (78%), well to moderately differentiated (Gleason score 6, 69%) and organ confined (pT2, 66%). 
Comparison between unifocal and multifocal tumours
A comparative analysis of patient and tumour characteristics of unifocal versus multifocal disease is presented in Table 3 . No significant difference in age, PSA, proportion of tumours with Gleason score X7, non-organ confined disease and TTV was observed between unifocal and multifocal cases.
Characteristics of tumour foci
In total, 270 tumour foci ranging from 0.002 to 24 cm 3 in volume were identified among the 100 whole-mount specimens (Table 4 ). Figure 1 illustrates the distribution of the number of foci per prostate. In multifocal disease, among the 170 satellite foci, 148 (87%) were o0.5 cm 3 and 169 (99.4%) had Gleason score p6. There were 25 (32.1%) specimens that had at least 2 tumour foci within the gland with different Gleason score. However, there was no case in which a satellite focus had a higher Gleason score than the index lesion of the specimen. Two satellite foci were found to extend extracapsularly. In one case, there were two foci in the specimen and both the index (1.24 cm 3 ) and the secondary focus (1.15 cm 3 ) extended beyond the capsule. In the other case, it was a secondary focus with volume 0.84 cm 3 that extended beyond the capsule, whereas the index lesion was organ confined. No satellite foci were found to invade the seminal vesicles. A strong relationship was observed between TTV in the specimen and volume of the index lesion of each multifocal case (Po0.01) (Figure 2) . The R 2 value shows that the value of the index lesion explains 90.5% of the variance in TTV in the specimen. were suitable for focal ablation that is, organ confined, Gleason score p7 tumours. Figure 3 illustrates the proportion of patients with multifocal disease suitable for focal index lesion ablation. Among the 78 multifocal cases, 37 patients were with organ confined, Gleason score p7 cancer, in which the total volume of the secondary foci was o0.5 cm 3 , with the Gleason score of p6 (Figure 3) . Therefore, in toto, there were 51 (14 unifocal and 37 multifocal) patients in this series who could be considered suitable for focal ablation.
Hemiablation. Another manner of delivering focal therapy is hemiablation. The same cohort of cases was analysed to determine the proportion that would be suitable for hemiablation as opposed to focal ablation.
Among the 14 unilateral cases, 10 patients were suitable for hemiablation that is, organ confined, Gleason score p7 tumour, disease limited to one side of the urethra. Among the 86 bilateral cases, 35 patients were with organ confined, Gleason score p7, bilateral and multifocal disease in which the index lesion was confined to one lobe and secondary foci in the contralateral side had total volume o0.5 cm 3 and Gleason score p6 (Figure 4) . Therefore, in toto, there were 45 (10 unilateral and 35 bilateral) patients in this series who could be considered suitable for hemiablation if index lesion ablation was considered an appropriate focal therapy strategy.
Three typical cases are illustrated in Figures 5-7 .
Discussion
The concept of focal therapy in PCa, in which only areas of cancer are treated, offers an opportunity for effective therapy with minimal morbidity. As PCa is multifocal in the majority of cases, the concept of ablating only the index lesion with the remaining clinically insignificant foci undergoing surveillance has evolved. Recent studies have suggested that only a very small minority of men undergoing radical prostatectomy have pathologically unilateral disease with low risk features that may be amenable to hemiablation of the prostate. 8, 23 However, neither of these groups evaluated the proportion of patients with bilateral disease with clinically insignificant tumour foci (o0.5 cm 3 tumour volume, Gleason score p6) on the side contralateral to the index lesion. Role of prostate cancer focality in focal therapy M Karavitakis et al
To the best of our knowledge, our study is the first to address the issue of tumour focality and index lesion from a focal therapy strategy. In our series, most PCas were multifocal (78%) and bilateral (86%), similar to those recorded in other countries. Contrary to other studies, 4 ,24 our analysis showed no apparent association between tumour focality and pathological features of poor prognosis. Furthermore, our data highlight the significance of the index lesion as an important pathological feature in PCa. In fact, Gleason score, tumour volume, extracapsular extension and seminal vesicle invasion were almost invariably determined by the largest tumour focus within the gland. Satellite lesions tended to be small and well differentiated.
As yet, no definitive conclusions can be reached from our analysis about the biological significance of tumour focality due to the lack of sufficient follow-up data; however, Noguchi et al. 25 examined the prognostic significance of secondary tumours in the prostate and showed that multifocal tumours were not associated with adverse features of prostatectomy specimens. By contrast, they found that multifocal disease had fewer cases of disease progression. In other words, when men were stratified by tumour focality and secondary cancer volume, PSA failure-free survival rates were consistently higher in the multifocal group with smaller secondary cancers than in the unifocal group. This suggests that multifocality per se is not a risk factor for disease progression in the prostate, and as such, patients harbouring multifocal tumours should not be excluded a priori for focal prostate therapy. Most importantly, the Stanford group elegantly demonstrated that progression was related to the index lesion and not the secondary foci. 13 Our analysis of the histopathological characteristics of the index lesion demonstrates that index lesion ablation may be a possible therapeutic strategy under the umbrella of focal therapy. Indeed, two groups have already commenced prospective trials evaluating the role of ablating the dominant lesion in clinically localized PCa. The MD Anderson Group (Protocol ID: 2008-0244NCT00877682) is using cryotherapy, and the UK London Group (Protocol ID: 09/H0714/7) is using highintensity focused ultrasound. It is important to recognize that such data point only to a possible relationship between size and cancer progression, but do not prove it. There were two foci in our series in which a secondary focus and not the index lesion demonstrated extracapsular extension. Interestingly, in both of these specimens, the secondary focus in question actually measured 40.5 cm 3 and could be regarded as a significant lesion in its own right on volume criteria. A prostate need not necessarily have just one index lesion. Ruijter et al. 22 examined a series of 61 radical prostatectomy specimens obtained from patients with palpable disease and found that a quarter of the tumours with extracapsular extension in multifocal disease were not the index lesion. Importantly, two of these secondary tumours extended beyond the prostatic capsule, influencing the pathological stage, whereas the largest tumour in the same specimen remained organ confined. Thus, they hypothesized that the index tumour may not always be representative of the pathological stage. Similarly, other investigators observed that even small foci, down to 0.2 cm 3 in size, may show a significant release of tumour cells into the bloodstream 26 and can lead to lymph node metastasis. 27 As Miller and Cygan 10 pointed out, tumours need not acquire a large volume before they become locally invasive.
Nonetheless, we have shown that among a cohort of UK patients undergoing radical prostatectomy for clinically localized PCa, there is a high proportion of men with cancer who seem suitable for focal ablation. Nearly half of our studied group had unifocal or multifocal organ confined disease suitable for focal ablation, if that included an index lesion protocol.
We acknowledge certain limitations to this study inherent in its design. First, our investigation focused exclusively on the histopathological analysis of the Role of prostate cancer focality in focal therapy M Karavitakis et al prostatectomy specimens and clinical outcome was not included in the study protocol. Therefore, no definitive conclusion can yet be drawn as to the prognostic effect of tumour focality and laterality on disease progression. However, it has been demonstrated by the Duke group that laterality does not affect disease progression. 20 Second, no preoperative data were included, which could illustrate the reliability of the current diagnostic methods to detect multifocal disease. We hope that future studies can be based on this report to better delineate the significance of PCa focality and prediction of the presence and location of the index lesion.
Conclusions
Multifocality is a common feature on radical prostatectomy specimens, but is not associated with pathological features of poor outcome. Tumour volume, Gleason grade, extracapsular extension and seminal vesicle invasion are almost invariably determined by the index lesion. Secondary foci are typically small-volume, welldifferentiated lesions, rarely associated with aggressive features. Such findings provide evidence in support of the proposition within focal therapy enthusiasts for targeting only the index lesion within the gland. However, prudence is required in deciding appropriate surveillance of the satellite lesions. Further studies are required to evaluate the clinical and biological implications of PCa focality, and molecular genetic, epigenetic and proteomic work needs to be carried out to determine whether these foci differ in their molecular and behavioural profiles.
